Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Pulmonary surfactant (PS) plays a vital role in regulating the surface tension of the alveoli, preventing alveolar collapse, and providing a spatial structure for gas exchange. Studies have found that there is a transporter of ATP-binding Cassette transporters A3 (ABCA3) on the outer membrane of lamellar bodies. Its function is to transport phospholipids and cholesterol in lamellar bodies out of the cell membrane and participate in the storage and secretion process of PS.
The post-transcriptional mRNA of the ABCA3 gene is approximately 6500 bp long and forms a primary translation product of approximately 190 kDa consisting of 1,704 amino acids after translation. At the N-terminus of the primary translation product, there is a signal sequence consisting of 5-6 amino acids, which has a guiding role in protein targeted delivery. Under targeted delivery, ABCA3 enters the rough endoplasmic reticulum for glycosylation folding. In vitro studies by Beers et al. found two glycosylation sites at positions 124 and 140 of the N-terminus. The study also showed that glycosylation folding plays a key role in protein folding, stabilization and cell localization. The primary translation product of the ABCA3 gene is glycosylated and folded in the endoplasmic reticulum, transported to the outer membrane of the lamellar body via vesicles or multivesicular bodies through the Golgi apparatus, and finally releases phospholipids and cholesterol into the alveolar space through exocytosis. . In immunoblotting, ABCA3 showed two protein bands with relative molecular masses of 190 000 and 170 000, respectively, demonstrating that ABCA3 was cleaved during transport.
Figure 1. Predicted topological model of the ABCA3 protein. (Beers, et al. 2013).
ABCA3 gene expression is regulated by a variety of factors and hormones. In lung tissue, thyroid transcription factor 1 (TTF1), signal transduction and transcriptional activator 3 (STAT3) are involved in the induction of ABCA3 gene expression, PS synthesis, and promotion of alveolar type II epithelial cell maturation. Hofmann et al. found that the transcription factor GATA-6, forkhead box protein A2 (FOXA2), CCAAT/enhancer binding protein a (C/EBPa), and activated T cell nuclear transcription factor 3 (NFATC3) initiate the gene by binding between 2591 bp and 1102 bp of exon 1 of the ABCA3 gene. Glucocorticoid upregulates the transcription level of the ABCA3 gene through a glucocorticoid response element that binds to the promoter region. When the glucocorticoid response element is deleted or the promoter sequence is mutated, the effect of dexamethasone disappears. Houda et al. found that the miR-200 family regulates the expression of ABCA3 gene by increasing the transcriptional activity of TTF-1 to promote the differentiation of alveolar type II epithelial cells.
ABCA3 Protein Physiological Function
ABCA3 belongs to a member of the A subfamily of the ABC superfamily and is highly expressed in lung tissue. The ABC superfamily is a large family with similar structure and material transport functions. It is widely distributed in various organisms from bacteria to humans and belongs to a class of ATP-driven pumps. ABCA3 has a similar structure to other subclasses of class A and consists of four domains: two transmembrane domains (TMD1 and TMD2) and two nucleotide binding domains (NBD1 and NBD2) located in the intracellular cytoplasm. TMD consists of six α helices that recognize the structure of various transmembrane transport substrates and complete transmembrane transport of substrate molecules. NBD is a site of ATP binding, NBD protein structure is highly conserved, and TMD has a variety of sequence structures, which indirectly reflects the diversity of substrate chemical structure. NBD binds to ATP and hydrolyzes ATP, which uses the energy of hydrolyzing ATP to transport the substrate out of the cell membrane. The function of ABCA3 in lung tissue is to transport cholesterol and phospholipids into the alveolar space to form PS, including phosphatidylcholine, phosphatidylglycerol, phosphatidylserine, and sphingomyelin.
ABCA3 and NRDS
Neonatal Respiratory Distress Syndrome (NRDS) is a respiratory distress and respiratory failure that occurs progressively after birth in neonates due to a lack of PS. NRDS is a multifactorial, multi-gene involved disease. In 2004, it was first discovered that mutations in the ABCA3 gene cause NRDS in term infants. Subsequent reports have also confirmed that ABCA3 gene mutation is one of the important causes of NRDS.
ABCA3 gene mutations are homozygous gene mutations and heterozygous gene mutations. The genetic phenotype and disease severity of different gene mutations are different. Farideh et al. reported that a NRDS full-term (38 weeks) male boy was found to have a homozygous mutation in the ABCA3 gene c. 604G> A (p.G 202R). Both parents were mutation carriers and close relatives were married. Mukhtar et al. reported that 3 children with NRDS were found to have homozygous mutations in c.4545delC, 2 patients had lung transplantation and 1 died. In addition, a study reported a male infant with NRDS after birth, but after a series of treatments without remission and died on the 72nd day after birth, ABCA3 gene detection found a composite mutation of c. 556C> A and c. 2632 delA.
The investigators performed ABCA3 gene testing in 11 children with NRDS and found c.2169 G>A (p.M723I), c.1010T>G (pV 337G), and c. 4972 A >G(p.S 1658G) exon variation, and ABCA3 gene Exon 30+2 T/G scissors site variation. Wambach et al. found that complex heterozygous mutations in mutations accounted for about 3/4 of all mutations, and the phenotypes were quite different. Homozygous mutations accounted for 1/4, and clinical manifestations were more serious. In a mouse model study, it was found that ABCA3 homozygous mutations usually die soon after birth, while ABCA3 heterozygous mutations can survive. This also confirms that the initial clinical manifestations of homozygous gene mutations are severe, and die in the first year after birth or in the first year of life; however, heterozygous mutations can survive to infancy or childhood, or even longer.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.